Figure 4.
Figure 4. The 7-gene signature accurately predicts bortezomib or lenalidomide responsiveness in further independent data sets. (A) Kaplan-Meier plot showing the PFS of patients who received single-agent bortezomib within the Millennium studies (n = 173) and who were predicted to benefit from bortezomib-based therapy (n = 38; broken line) or from RD therapy (n = 135; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (B) Kaplan-Meier plot showing the OS of patients who received single-agent bortezomib within the Millennium studies (n = 188) and who were predicted to benefit from bortezomib-based therapy (n = 40; broken line) or RD therapy (n = 148; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (C) HRs for PFS and OS of patients predicted to benefit from bortezomib-based therapy who received bortezomib in the Millennium studies. Predictions were made by the 7-gene signature, trained in PADIMAC with repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P values are those of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same. (D) Kaplan-Meier plot showing the PFS of patients who received RD within the PCL study (n = 18) and who were predicted to benefit (n = 8; solid line) or not (n = 10; broken line) from RD therapy by the 7-gene signature after training in PADIMAC. The P value is that obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of patients who received RD within the PCL study (n = 18) and who were predicted to benefit (n = 8; solid line) or not (n = 10; broken line) from RD therapy by the 7-gene signature after training in PADIMAC. The P value is that obtained from Cox regression analysis. (F) HRs for PFS and OS of patients predicted to benefit from lenalidomide-based therapy and who received RD in the PCL study. Predictions were made by the 7-gene signature, trained in PADIMAC with repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P value is that of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same.

The 7-gene signature accurately predicts bortezomib or lenalidomide responsiveness in further independent data sets. (A) Kaplan-Meier plot showing the PFS of patients who received single-agent bortezomib within the Millennium studies (n = 173) and who were predicted to benefit from bortezomib-based therapy (n = 38; broken line) or from RD therapy (n = 135; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (B) Kaplan-Meier plot showing the OS of patients who received single-agent bortezomib within the Millennium studies (n = 188) and who were predicted to benefit from bortezomib-based therapy (n = 40; broken line) or RD therapy (n = 148; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (C) HRs for PFS and OS of patients predicted to benefit from bortezomib-based therapy who received bortezomib in the Millennium studies. Predictions were made by the 7-gene signature, trained in PADIMAC with repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P values are those of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same. (D) Kaplan-Meier plot showing the PFS of patients who received RD within the PCL study (n = 18) and who were predicted to benefit (n = 8; solid line) or not (n = 10; broken line) from RD therapy by the 7-gene signature after training in PADIMAC. The P value is that obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of patients who received RD within the PCL study (n = 18) and who were predicted to benefit (n = 8; solid line) or not (n = 10; broken line) from RD therapy by the 7-gene signature after training in PADIMAC. The P value is that obtained from Cox regression analysis. (F) HRs for PFS and OS of patients predicted to benefit from lenalidomide-based therapy and who received RD in the PCL study. Predictions were made by the 7-gene signature, trained in PADIMAC with repeated (n = 100) training/validation splits (signature). The HRs are compared with a null data set of HRs obtained after permutations of the assignments (null). The P value is that of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed and null performances are the same.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal